Resurrect Bio

The company's core technology centers on its proprietary platform that identifies and reactivates suppressed or lost native resistance genes (R-genes). This platform utilizes FloraFold®, a specialized AI and computational biology tool that predicts how pathogen proteins interact with and disable a plant's immune receptors. By pinpointing these interactions, Resurrect Bio can apply precise gene-editing techniques to make minimal changes to a crop's native genes, effectively restoring their ability to defend against diseases caused by fungi, oomycetes, and nematodes. This approach avoids introducing foreign DNA and can develop new resistance traits in one to two years, significantly faster than conventional breeding.

Resurrect Bio operates on a B2B model, partnering with seed companies. Its revenue streams include upfront licensing fees, milestone payments, and downstream profit-sharing or royalties on seeds sold with their traits. The company develops traits independently for licensing and also engages in joint development agreements. In March 2026, Resurrect Bio announced such an agreement with Corteva to combat diseases in U.S. corn production. The firm's primary focus is on major crops like soy, corn, and wheat, with plans to expand to rice, cotton, and various vegetables.

Financially, Resurrect Bio completed a seed round of £1.61M ($2.1M) in 2023. In February 2026, the company announced the initial closing of its Series A funding at $8.1 million, led by Corteva through its Corteva Catalyst platform, with participation from investors including Calculus Capital, Pymwymic, and AgFunder. These funds are intended to scale its high-throughput trait discovery platform, expand the team, and advance multiple products toward commercial partnerships.